MedTrace Logo

Open-label Study of Surufatinib in Japanese Patients

NCT05077384 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-09-16

No results posted yet for this study

Summary

This is a phase 1/2, open-label, multi-centre study of surufatinib in patients with unresectable, locally advanced, or recurrent nonhematologic malignancies who do not respond or are intolerant to standard of care.

Conditions

Interventions

DRUG

Surufatinib

Surufatinib 300 mg oral once daily

Sponsors & Collaborators

  • Hutchmed

    lead INDUSTRY

Principal Investigators

  • William Schelman, MD · Hutchmed

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-02
Primary Completion
2024-09-06
Completion
2025-01-17
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05077384 on ClinicalTrials.gov